Stockreport

Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug [Yahoo! Finance]

Madrigal Pharmaceuticals, Inc.  (MDGL) 
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am Check Earnings Report
US:NASDAQ Investor Relations: madrigalpharma.com
PDF patients in a trial of Rezdiffra (resmetirom), a drug candidate for compensated non-alcoholic steatohepatitis (NASH) cirrhosis. MAESTRO-NASH OUTCOMES is a double-blind [Read more]